Loading
A blood test that needs no tumour sample found leftover cancer DNA in a third of women after treatment for triple-negative breast cancer, and those women were far more likely to relapse; it agreed closely with the tests that first sequence the tumour.
Prognostic and exploratory analysis of the ctDNA surveillance period of c-TRAK TN, a multicentre phase 2 study in triple-negative breast cancer at moderate to high risk of recurrence. Plasma was collected every three months for up to two years after adjuvant therapy. A tissue-free methylation assay was compared with digital PCR and whole-exome-powered tumour-informed assays across 1,026 samples from 159 patients.
Residual-disease testing may not need the tumour to be sequenced first, which would remove the slowest step of tumour-informed assays; the comparison with tumour-informed results in the same patients is the evidence that matters.
Shares JAMA Oncology, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, JAMA Oncology, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC).